GlassScriptPhysician profile
Richard Phelps
NPI 1942490016
$9,680.54
in general payments reported to CMS, 2019-2025
30 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $1,153 · 2021: $2,042 · 2022: $1,549 · 2023: $1,434 · 2024: $1,597 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,452 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,451.61 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,740.76 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $902.22 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $843.34 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $736.14 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $730.78 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $658.50 | 2019-2025 | Spravato |
| Allergan, INC. | $655.47 | 2019-2020 | |
| Lundbeck LLC | $623.49 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $460.23 | 2022-2024 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $379.93 | 2019-2022 | |
| Bausch Health US, LLC | $343.90 | 2019-2025 | Aplenzin |
| Almatica Pharma LLC | $285.97 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Avanir Pharmaceuticals, INC. | $203.64 | 2020-2021 | |
| Alkermes, INC. | $191.34 | 2021-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $176.73 | 2024-2025 | Cobenfy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $125.34 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $112.75 | 2023-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $71.51 | 2020-2023 | Jornay Pm |
| Tris Pharma INC | $70.77 | 2024-2025 | Dyanavel Xr |
| Alfasigma USA, INC. | $68.73 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $61.58 | 2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $43.69 | 2021 | |
| Idorsia Pharmaceuticals US INC | $32.34 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $29.93 | 2022-2025 | Auvelity |
| Tempus Ai, INC | $27.95 | 2024 | |
| Eisai INC. | $26.36 | 2020-2021 | |
| Noven Therapeutics, LLC | $22.47 | 2024 | Secuado, Xelstrym |
| Shire North American Group INC | $20.22 | 2019 | |
| Livanova USA, INC. | $17.53 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Merck Sharp & Dohme LLC | $16.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Phelps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.